Opinion
Video
Author(s):
Panelists discuss how Bruton tyrosine kinase (BTK) inhibitors are reshaping the evolving treatment landscape for chronic spontaneous urticaria (CSU) by providing targeted therapeutic options that address underlying mast cell activation.